These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 29264583)

  • 21. Living donor versus deceased donor liver transplantation for early irresectable hepatocellular carcinoma.
    Lo CM; Fan ST; Liu CL; Chan SC; Ng IO; Wong J
    Br J Surg; 2007 Jan; 94(1):78-86. PubMed ID: 17016793
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Living donor liver transplantation for advanced hepatocellular carcinoma including macrovascular invasion.
    Bhatti ABH; Naqvi W; Khan NY; Zia HH; Dar FS; Khan ZA; Rana A
    J Cancer Res Clin Oncol; 2022 Jan; 148(1):245-253. PubMed ID: 34117916
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Mammalian target of rapamycin inhibitors are associated with lower rates of hepatocellular carcinoma recurrence after liver transplantation: a systematic review.
    Cholongitas E; Mamou C; Rodríguez-Castro KI; Burra P
    Transpl Int; 2014 Oct; 27(10):1039-49. PubMed ID: 24943720
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Living donor liver transplantation or hepatic resection combined with intraoperative radiofrequency ablation for Child-Pugh A hepatocellular carcinoma patient with Multifocal Tumours Meeting the University of California San Francisco (UCSF) criteria.
    Xu X; Pu X; Jiang L; Huang Y; Yan L; Yang J; Wen T; Li B; Wu H; Wang W
    J Cancer Res Clin Oncol; 2021 Feb; 147(2):607-618. PubMed ID: 32852635
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Early use of everolimus improved renal function after adult deceased donor liver transplantation.
    Lee S; Kim JM; Kim S; Rhu J; Choi GS; Joh JW
    Korean J Transplant; 2021 Mar; 35(1):8-14. PubMed ID: 35769619
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Tacrolimus and Everolimus de novo versus minimization of standard dosage of Tacrolimus provides a similar renal function at one year after liver transplantation: a case-control matched-pairs analysis.
    Mocchegiani F; Montalti R; Nicolini D; Svegliati Baroni G; Benedetti A; Risaliti A; Vivarelli M
    Ann Transplant; 2014 Oct; 19():545-50. PubMed ID: 25347718
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Very Early Introduction of Everolimus in De Novo Liver Transplantation: Results of a Multicenter, Prospective, Randomized Trial.
    Cillo U; Saracino L; Vitale A; Bertacco A; Salizzoni M; Lupo F; Colledan M; Corno V; Rossi G; Reggiani P; Baccarani U; Bresàdola V; De Carlis L; Mangoni I; Ramirez Morales R; Agnes S; Nure E
    Liver Transpl; 2019 Feb; 25(2):242-251. PubMed ID: 30592371
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The impact of everolimus in reducing cytomegalovirus events in kidney transplant recipients on steroid-avoidance strategy: 3-year follow-up of a randomized clinical trial.
    de Sandes-Freitas TV; Pinheiro PMA; Sales MLMBO; Girão CM; Campos ÉF; Esmeraldo RM
    Transpl Int; 2018 Dec; 31(12):1345-1356. PubMed ID: 29969826
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Outcome of ABO-incompatible adult living-donor liver transplantation for patients with hepatocellular carcinoma.
    Yoon YI; Song GW; Lee SG; Hwang S; Kim KH; Kim SH; Kang WH; Cho HD; Jwa EK; Kwon JH; Tak EY; Kirchner VA
    J Hepatol; 2018 Jun; 68(6):1153-1162. PubMed ID: 29452208
    [TBL] [Abstract][Full Text] [Related]  

  • 30. University of California at San Francisco criteria can be applied to living donor liver transplantation for hepatocellular carcinoma: single-center preliminary results in 27 patients.
    Jiang XZ; Yan LN; Wen TF; Li B; Zeng Y; Zhao JC; Wang WT; Yang JY; Xu MQ; Chen ZY; Ma YK; Li FG; Gong G
    Transplant Proc; 2008 Jun; 40(5):1476-80. PubMed ID: 18589132
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Mechanistic analyses in kidney transplant recipients prospectively randomized to two steroid free regimen-Low dose Tacrolimus with Everolimus versus standard dose Tacrolimus with Mycophenolate Mofetil.
    Traitanon O; Mathew JM; Shetty A; Bontha SV; Maluf DG; El Kassis Y; Park SH; Han J; Ansari MJ; Leventhal JR; Mas V; Gallon L
    PLoS One; 2019; 14(5):e0216300. PubMed ID: 31136582
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Preventive effect of early introduction of everolimus and reduced-exposure tacrolimus on renal interstitial fibrosis in de novo living-donor renal transplant recipients.
    Ishida H; Ogura G; Uehara S; Takiguchi S; Nakagawa Y; Hamano N; Koizumi M; Wada T; Fukagawa M; Nakamura M
    Clin Exp Nephrol; 2020 Mar; 24(3):268-276. PubMed ID: 31792639
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A revised scoring system utilizing serum alphafetoprotein levels to expand candidates for living donor transplantation in hepatocellular carcinoma.
    Yang SH; Suh KS; Lee HW; Cho EH; Cho JY; Cho YB; Kim IH; Yi NJ; Lee KU
    Surgery; 2007 May; 141(5):598-609. PubMed ID: 17462459
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Living donor liver transplantation for hepatocellular carcinoma in patients exceeding the UCSF criteria.
    Fouzas I; Sotiropoulos GC; Lang H; Nadalin S; Beckebaum S; Sgourakis G; Saner FH; Radtke A; Papanikolaou V; Baba HA; Paul A; Broelsch CE; Malagó M
    Transplant Proc; 2008 Nov; 40(9):3185-8. PubMed ID: 19010228
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Outcomes of Liver Transplantation for Hepatocellular Carcinoma Beyond the University of California San Francisco Criteria: A Single-center Experience.
    Victor DW; Monsour HP; Boktour M; Lunsford K; Balogh J; Graviss EA; Nguyen DT; McFadden R; Divatia MK; Heyne K; Ankoma-Sey V; Egwim C; Galati J; Duchini A; Saharia A; Mobley C; Gaber AO; Ghobrial RM
    Transplantation; 2020 Jan; 104(1):113-121. PubMed ID: 31233480
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Living donor liver transplantation for hepatocellular carcinoma at the University of Tokyo Hospital.
    Togashi J; Akamastu N; Kokudo N
    Hepatobiliary Surg Nutr; 2016 Oct; 5(5):399-407. PubMed ID: 27826554
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Combination of morphologic criteria and α-fetoprotein in selection of patients with hepatocellular carcinoma for liver transplantation minimizes the problem of posttransplant tumor recurrence.
    Grąt M; Kornasiewicz O; Lewandowski Z; Hołówko W; Grąt K; Kobryń K; Patkowski W; Zieniewicz K; Krawczyk M
    World J Surg; 2014 Oct; 38(10):2698-707. PubMed ID: 24858191
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Tablets or oral suspension for posaconazole in lung transplant recipients? Consequences for trough concentrations of tacrolimus and everolimus.
    Chanoine S; Gautier-Veyret E; Pluchart H; Tonini J; Fonrose X; Claustre J; Bedouch P; Stanke-Labesque F
    Br J Clin Pharmacol; 2021 Feb; 87(2):427-435. PubMed ID: 32472569
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Everolimus-based immunosuppression in patients with hepatocellular carcinoma at high risk of recurrence after liver transplantation: a case series.
    Ferreiro AO; Vazquez-Millán MA; López FS; Gutiérrez MG; Diaz SP; Patiño MJ
    Transplant Proc; 2014 Dec; 46(10):3496-501. PubMed ID: 25498079
    [TBL] [Abstract][Full Text] [Related]  

  • 40. When to call it off: defining transplant candidacy limits in liver donor liver transplantation for hepatocellular carcinoma.
    Bhatti ABH; Qureshi AI; Tahir R; Dar FS; Khan NY; Zia HH; Riyaz S; Rana A
    BMC Cancer; 2020 Aug; 20(1):754. PubMed ID: 32787864
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.